OBJECTIVE: To identify significant clinical factors associated with prostate cancer (PCa) upgrading the low-risk PCa patients graded according to the modified Gleason score system. MATERIALS AND METHODS: The logistic regression model was used to evaluate the records of 438 patients. RESULTS: There were 170 cases (38.8%) of low-risk PCa and tumors were upgraded in 111 patients (65.3%). Only prostate specific antigen (PSA) and the proportion of positive cores (P+) were independent predictors of tumor upgrading. Further exploration was investigated by categorizing and regressing PSA (≤ 5.0 vs. > 5.0 ng/ml) and P+ (≤ 0.20 vs. > 0.20). The odds ratio of PSA > 5 ng/ml was 1.32 and of P+ > 0.20 was 2.71. The population was stratified into very low-risk with PSA ≤ 5 ng/ml and P+ ≤ 0.20 (class A), low-risk with PSA > 5 ng/ml and P+ ≤ 0.20 (class B), intermediate risk with PSA ≤ 5 ng/ml and P+ > 0.20 (class C), and high risk with PSA > 5 ng/ml and P+ 0.20 (class D). Upgrading rates were extremely low in class A (9%), extremely high in D (50.5%), and moderate (20%) in B and C. CONCLUSION: Patients diagnosed with low-risk PCa at biopsy are a heterogeneous population because they include subsets with undetected high-grade disease. Significant clinical predictors of upgrading include the PSA value and P+. In low-risk PCa, we identified a high-risk upgrading subgroup that needed repeat biopsies in order to reclassify the tumor grade and to reassess the clinical risk category.
OBJECTIVE: To identify significant clinical factors associated with prostate cancer (PCa) upgrading the low-risk PCa patients graded according to the modified Gleason score system. MATERIALS AND METHODS: The logistic regression model was used to evaluate the records of 438 patients. RESULTS: There were 170 cases (38.8%) of low-risk PCa and tumors were upgraded in 111 patients (65.3%). Only prostate specific antigen (PSA) and the proportion of positive cores (P+) were independent predictors of tumor upgrading. Further exploration was investigated by categorizing and regressing PSA (≤ 5.0 vs. > 5.0 ng/ml) and P+ (≤ 0.20 vs. > 0.20). The odds ratio of PSA > 5 ng/ml was 1.32 and of P+ > 0.20 was 2.71. The population was stratified into very low-risk with PSA ≤ 5 ng/ml and P+ ≤ 0.20 (class A), low-risk with PSA > 5 ng/ml and P+ ≤ 0.20 (class B), intermediate risk with PSA ≤ 5 ng/ml and P+ > 0.20 (class C), and high risk with PSA > 5 ng/ml and P+ 0.20 (class D). Upgrading rates were extremely low in class A (9%), extremely high in D (50.5%), and moderate (20%) in B and C. CONCLUSION:Patients diagnosed with low-risk PCa at biopsy are a heterogeneous population because they include subsets with undetected high-grade disease. Significant clinical predictors of upgrading include the PSA value and P+. In low-risk PCa, we identified a high-risk upgrading subgroup that needed repeat biopsies in order to reclassify the tumor grade and to reassess the clinical risk category.
Authors: Ian M Thompson; Chen Chi; Donna Pauler Ankerst; Phyllis J Goodman; Catherine M Tangen; Scott M Lippman; M Scott Lucia; Howard L Parnes; Charles A Coltman Journal: J Natl Cancer Inst Date: 2006-08-16 Impact factor: 13.506
Authors: Jen-Jane Liu; Daphne Y Lichtensztajn; Scarlett Lin Gomez; Weiva Sieh; Benjamin I Chung; Iona Cheng; James D Brooks Journal: Pathology Date: 2014-06 Impact factor: 5.306
Authors: Fadi Brimo; Rodolfo Montironi; Lars Egevad; Andreas Erbersdobler; Daniel W Lin; Joel B Nelson; Mark A Rubin; Theo van der Kwast; Mahul Amin; Jonathan I Epstein Journal: Eur Urol Date: 2012-10-17 Impact factor: 20.096
Authors: Brandon K Isariyawongse; Leon Sun; Lionel L Bañez; Cary Robertson; Thomas J Polascik; Kelly Maloney; Craig Donatucci; David Albala; Vladimir Mouraviev; John F Madden; Judd W Moul Journal: Urology Date: 2008-04-02 Impact factor: 2.649
Authors: Antonio Benito Porcaro; Marco Sebben; Paolo Corsi; Alessandro Tafuri; Tania Processali; Marco Pirozzi; Nelia Amigoni; Riccardo Rizzetto; Giovanni Cacciamani; Arianna Mariotto; Alberto Diminutto; Matteo Brunelli; Vincenzo De Marco; Salvatore Siracusano; Walter Artibani Journal: J Robot Surg Date: 2019-04-05
Authors: Kathryn L Penney; Svitlana Tyekucheva; Jacob Rosenthal; Habiba El Fandy; Ryan Carelli; Stephanie Borgstein; Giorgia Zadra; Giuseppe Nicolò Fanelli; Lavinia Stefanizzi; Francesca Giunchi; Mark Pomerantz; Samuel Peisch; Hannah Coulson; Rosina Lis; Adam S Kibel; Michelangelo Fiorentino; Renato Umeton; Massimo Loda Journal: Mol Cancer Res Date: 2020-11-09 Impact factor: 5.852
Authors: Antonio B Porcaro; Alessandro Tafuri; Marco Sebben; Paolo Corsi; Tania Processali; Marco Pirozzi; Nelia Amigoni; Riccardo Rizzetto; Aliasger Shakir; Giovanni Cacciamani; Arianna Mariotto; Matteo Brunelli; Riccardo Bernasconi; Giovanni Novella; Vincenzo De Marco; Walter Artibani Journal: Arab J Urol Date: 2019-05-30